Clinically Significant Drug-Drug Interaction Between Methadone and Cannabidiol

@article{Madden2020ClinicallySD,
  title={Clinically Significant Drug-Drug Interaction Between Methadone and Cannabidiol},
  author={Kevin Madden and Kimberson Tanco and Eduardo Bruera},
  journal={Pediatrics},
  year={2020},
  volume={145}
}
Cannabidiol is often viewed as a benign substance, but it can cause dramatic drug toxicity when used with other medications. The use of cannabidiol products in pediatric patients is becoming more frequent because of the increased ease of accessibility. This case report illustrates the potential for cannabidiol to interact with stable medication regimens. A 13-year-old girl with metastatic cancer and chronic pain presented with increased sleepiness and fatigue. She had been started on 7.5 mg of… 

Does Cannabidiol Have a Benefit as a Supportive Care Drug in Cancer?

A small pilot study has shown promise for a role of CBD in the psychological symptoms associated with advanced cancer, and it is advocated that CBD be used in supervised clinical trials, so that efficacy and adverse effects can be closely monitored.

Cannabidiol drug interaction considerations for prescribers and pharmacists

An overview of evidence-based pharmacokinetic predictions and general guidance about the dose range at which clinically relevant cannabidiol drug interactions are likely is provided.

Potential Pharmacokinetic Drug-Drug Interactions between Cannabinoids and Drugs Used for Chronic Pain

This brief review is to assess the interactions between cannabinoids and pain medication through drug transporters (ATP-binding cassette superfamily members) and/or metabolizing enzymes (cytochromes P450 and glucuronyl transferases).

Cannabidiol: pharmacology and therapeutic targets

The molecular targets, pharmacokinetics, and safety and abuse liability of CBD are reviewed; additionally, the extant evidence on its potential therapeutic effects for neurological disorders, pain, inflammation, conditions related to immune function, psychiatric disorders, and substance use are described.

Cannabidiol: pharmacology and therapeutic targets

The molecular targets, pharmacokinetics, and safety and abuse liability of CBD are reviewed; additionally, the extant evidence on its potential therapeutic effects for neurological disorders, pain, inflammation, conditions related to immune function, psychiatric disorders, and substance use are described.

A primer on medicinal cannabis safety and potential adverse effects.

  • J. Arnold
  • Medicine
    Australian journal of general practice
  • 2021
The aim of this review is to provide a primer on the safety issues that need to be considered with medicinal cannabis, and to minimise dose-related toxicities and the potential for drug-drug interactions with concomitant medications.

Cannabidiol and epilepsy in Brazil: a current review.

CBD is a recognized novel treatment for epilepsy and future well-designed studies and public health strategies are needed to offer widespread access to CBD, and to improve the quality of life of people living with epilepsy in Brazil.

Therapeutic Efficacy of Cannabidiol (CBD): a Review of the Evidence From Clinical Trials and Human Laboratory Studies

Rigorous, controlled evidence for the therapeutic efficacy of CBD is lacking for many health conditions, including epilepsy, anxiety, pain/inflammation, schizophrenia, various substance use disorders, post-traumatic stress disorder, and others.

Clinical Relevance of Drug Interactions with Cannabis: A Systematic Review

Evidence is provided for both the low probability of the occurrence of clinically relevant drug interactions and the lack of evidence regarding cannabis–drug interactions.

References

SHOWING 1-10 OF 27 REFERENCES

Methadone: a review of drug-drug and pathophysiological interactions

This work set out to describe drug-drug interactions as well as physiological and pathophysiological factors that may impact the pharmacokinetics of methadone, and conducted a systematic search for papers and related abstracts published between 1966 and 2010.

Evidence of a clinically significant drug‐drug interaction between cannabidiol and tacrolimus

An important concern for the transplant community with the increasing legalization of cannabis and advent of an FDA‐approved CBD product is delineated, for the first time, a significant drug‐drug interaction between the purified CBD product and tacrolimus.

Role of Cannabinoids in Multiple Sclerosis

An increasing amount of evidence is now emerging to confirm anecdotal reports of symptomatic improvement, particularly for muscle stiffness and spasms, neuropathic pain and sleep and bladder disturbance, in patients with MS treated with cannabinoids.

Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders

CBD bears investigation in epilepsy and other neuropsychiatric disorders, including anxiety, schizophrenia, addiction, and neonatal hypoxic‐ischemic encephalopathy, however, data from well‐powered double‐blind randomized, controlled studies on the efficacy of pure CBD for any disorder is lacking.

Drug–drug interaction between clobazam and cannabidiol in children with refractory epilepsy

Under an expanded access investigational new drug (IND) trial, cannabidiol (CBD) is being studied as a possible adjuvant treatment of refractory epilepsy in children, and it is predicted a drug–drug interaction.

Cannabidiol in Anxiety and Sleep: A Large Case Series.

A large retrospective case series involving clinical application of CBD for anxiety and sleep complaints as an adjunct to usual treatment found CBD was well tolerated in all but 3 patients.

Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up

These data provide limited evidence for a longer term treatment effect of cannabinoids in multiple sclerosis, and a long term placebo controlled study is now needed to establish whether cannabinoids may have a role beyond symptom amelioration in MS.

In vitro and in vivo efficacy of non-psychoactive cannabidiol in neuroblastoma.

The results demonstrate the antitumourigenic action of cbd on nbl cells and support its exploitation as an effective anticancer drug in the management of nbl.